Navigation Links
PDL BioPharma Announces Fourth Quarter and Full Year 2011 Financial Results

INCLINE VILLAGE, Nev., Feb. 23, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and full year ended December 31, 2011.


Total revenues in 2011 were $362 million, compared to $345 million in 2010, with royalty revenues increasing two percent over full year 2010. For the fourth quarter of 2011, total revenues were $72.8 million, compared to $76.1 million in the fourth quarter of 2010.

Royalty revenues for the fourth quarter of 2011 are based on third quarter product sales by PDL's licensees. The fourth quarter 2011 revenue decline is primarily driven by reduced royalties from third quarter 2011 sales of Avastin® and Herceptin®, which are marketed by Genentech and Roche, partially offset by increased royalties from third quarter 2011 sales of Lucentis® which is marketed by Genentech and Novartis, and Tysabri®, which is marketed by Elan and Biogen Idec. Royalty revenue for the fourth quarter and 2011 are net of payments made under our February 2011 settlement agreement with Novartis Pharma AG.

Operating expenses in 2011 were $18.3 million, compared with $133.9 million in 2010. Included in operating expenses in 2010 is a $92.5 million legal settlement with MedImmune and $41.4 million in general and administrative expenses. For the fourth quarter of 2011, general and administrative expenses were $4.8 million compared with $12.1 million for the same period of 2010.

Net income in 2011 was $199.4 million, or $1.15 per diluted share as compared with net income of $91.9 million in 2010 or $0.54 per diluted share. Net income for the fourth quarter of 2011 was $38.9 million or $0.24 per diluted share as compared with a net loss of $24.5 million or $(0.18) per diluted share for the same period of 2010. Adjusting for effects of certain convertible note transactions throughout the year, non-GAAP net income for 2011 was $201.6 million, or $1.17 per diluted share. Non-GAAP net income was $168.4 million, or $0.97 per diluted share in 2010, adjusting for the legal settlement with MedImmune and the effects of certain convertible note transactions in that year. Non-GAAP net income for the fourth quarter of 2011 was $39.6 million, or $0.24 per diluted share, compared to non-GAAP net income of $35.0 million, or $0.20 per diluted share for the fourth quarter of 2010.

Net cash provided by operating activities in 2011 was $169.8 million, compared with $184.3 million in 2010. At December 31, 2011, PDL had cash, cash equivalents and investments of $227.9 million, compared with $248.2 million at December 31, 2010.

Recent Developments2012 Dividends On January 18, 2012, PDL's Board of Directors declared regular quarterly dividends of $0.15 per share of common stock, payable on March 14, June 14, September 14 and December 14 of 2012 to stockholders of record on March 7, June 7, September 7 and December 7 of 2012, the record dates for each of the dividend payments, respectively.

Exchange and Retirement of Convertible NotesIn January and February 2012, we completed public and privately negotiated exchange transactions where we exchanged and subsequently retired $179.0 million aggregate principal amount, representing over 99% of our 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), for $179.0 million aggregate principal amount of new 2.875% Series 2012 Convertible Senior Notes due February 15, 2015 (Series 2012 Notes). In the public exchanges, we made one-time cash payments of $5.00 for each $1,000 principal amount tendered for a total cash incentive payment of $0.8 million. Following settlement of the exchanges on February 2, 2012, $1.0 million of our February 2015 Notes and $179.0 million of our Series 2012 Notes were outstanding. Our Series 2012 Notes net share settle. The effect of issuing $179.0 million aggregate principal of our Series 2012 Notes with the net share settle feature in exchange for our February 2015 Notes was the reduction of 27.8 million shares of potential dilution to our stockholders.

Revenue Guidance for 2012As previously announced, PDL will continue to provide revenue guidance for each quarter in the third month of that quarter. First quarter 2012 revenue guidance will be provided in early March.

Conference Call DetailsPDL will hold a conference call to discuss financial results at 4:30 p.m. ET today, February 23, 2012.

To access the live conference call via phone, please dial (877) 677-9122 from the United States and Canada or (708) 290-1401 internationally. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through March 1, 2012, and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 50024423.

To access the live and subsequently archived webcast of the conference call, go to the Company's website at and go to "Company Presentations & Events." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharmaPDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. For more information, please visit

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking StatementsThis press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new royalty bearing assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission and updated by subsequent Quarterly Reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.PDL BIOPHARMA, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS DATA(Unaudited)(In thousands, except per share amounts)Three Months EndedYear EndedDecember 31,December 31,2011201020112010RevenuesRoyalties$ 72,808$  74,629$ 351,641$ 343,475License and other-1,50010,4001,500Total revenues72,80876,129362,041344,975Operating ExpensesGeneral and administrative expenses4,82212,05618,33841,396Legal Settlement-92,500-92,500Total operating expenses4,822104,55618,338133,896Operating income (loss)67,986(28,427)343,703211,079Non-operating expense, netGain (loss) on retirement or conversion of convertible notes-1,033(766)(17,648)Interest and other income, net130131593468Interest expense(8,161)(9,514)(36,102)(43,529)Total non-operating expense, net(8,031)(8,350)(36,275)(60,709)Income before income taxes59,955(36,777)307,428150,370Income tax expense (benefit)21,013(12,317)108,03958,496Net income (loss)$ 38,942$ (24,460)$ 199,389$   91,874Net income (loss) per shareBasic$
.54Cash dividends declared per common share$
.00Shares used to compute income (loss) per basic share139,680139,542139,663126,578Shares used to compute income (loss) per diluted share167,683139,542177,441178,801PDL BIOPHARMA, INC.RECONCILIATION OF GAAP FINANCIAL INFORMATION TO NON-GAAP(Unaudited)(In thousands, except non-GAAP net income per diluted share amounts)Three Months Ended December 31,Year Ended

December 31,2011201020112010Net income (loss)

$ 38,942$ (24,460)$ 199,389$   91,874Add back:Legal settlement expense, net of estimated taxes

-60,125-60,125(Gain) loss on retirement or conversion of convertible notes, net of estimated taxes

-(660)49816,431Amortization of debt discount for May 2015 Notes, net of estimated taxes

696-1,716-Non-GAAP net income

39,63835,005201,603168,430Add back interest expense for implied conversion of convertible notes included in determination of fully diluted shares, net of estimated taxes

1,1221,1055,5445,087Non-GAAP income used to compute non-GAAP net income per diluted share

$ 40,760$  36,110$ 207,147$ 173,517Shares used to compute net income per diluted share

167,683139,542177,441178,801Adjustment to shares issued to induce note conversion to common stock (1)

-(185)-(73)Effect of dilutive stock options(2)

-12--Restricted stock outstanding(2)

-115--Assumed conversion of 2012 Notes(2)

-23,399--Assumed conversion of February 2015 Notes(2)

-16,777--Shares used to compute non-GAAP net income per diluted share

167,683179,660177,441178,728Non-GAAP net income per diluted share

.97(1) Shares for the quarter and year ended December 31, 2010, exclude the weighted average effect of the shares issued as an incentive to induce conversion of the 2023 Notes in August 2010. (2) Shares for the quarter ended December 31, 2010, include the dilutive effect of stock options, restricted stock outstanding, assumed conversion of the 2012 Notes and assumed conversion of the February 2015 Notes. These shares were excluded from the GAAP net loss per diluted share calculation because they were anti-dilutive.PDL BIOPHARMA, INC. GENERAL AND ADMINISTRATIVE EXPENSE DATA(Unaudited)(In thousands) Three Months Ended December 31,Year Ended

December 31,2011201020112010Operating expenses:General and administrativeCompensation and benefits$ 1,470$
,103$   4,428$
4,065Legal expense1,7808,4947,94229,315Professional services6733252,6742,943Insurance169185724793Stock-based compensation131138387662Depreciation14145891Other5851,7972,1253,527Total general and administrative expenses4,82212,05618,33841,396Legal settlement-92,500-92,500Total operating expenses$ 4,822$ 104,556$ 18,338$ 133,896PDL BIOPHARMA, INC. CONDENSED CONSOLIDATED BALANCE SHEET DATA(Unaudited)(In thousands) December 31,20112010Cash, cash equivalents and investments$  227,946$  248,229Total assets$  269,471$  316,666Convertible notes payable$  316,615$  310,428Non-recourse notes payable$
93,370$  204,270Total stockholders' deficit$ (204,273)$ (324,182)PDL BIOPHARMA, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW DATA (Unaudited)(In thousands) Year Ended December 31,20112010Net income$ 199,389$   91,874Adjustments to reconcile net income to net cash provided by operating activities43,57421,777Changes in assets and liabilities(73,181)70,649Net cash provided by operating activities$ 169,782$ 184,300 PDL BIOPHARMA, INC. MIX OF EX-U.S. SALES AND EX-U.S.-BASED MANUFACTURING AND SALES

OF GENENTECH PRODUCTS(Unaudited)Three Months Ended Year EndedDecember 31,December 31,2011201020112010Avastin% Ex-U.S. Sold

53%51%55%50%% Ex-U.S.-based Manufactured and Sold

28%26%21%21%Herceptin% Ex-U.S. Sold

68%70%71%70%% Ex-U.S.-based Manufactured and Sold

26%40%35%44%Lucentis% Ex-U.S. Sold

60%55%59%56%% Ex-U.S.-based Manufactured and Sold

0%0%0%0%Xolair% Ex-U.S. Sold

40%35%40%35%% Ex-U.S.-based Manufactured and Sold


SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
3. Ondine Biopharma Announces Second Quarter 2008 Financial Results
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
6. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
7. Therapure Biopharma Inc. opens for business with first client contracts
8. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
9. China Biopharma Effects 1 for 100 Reverse Stock Split
10. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
11. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 ... ... today announced tighter software integration with MarkLogic, the Enterprise NoSQL database platform ... information to drive change. , Smartlogic’s Content Intelligence capabilities provide a robust ...
(Date:11/28/2015)... ... 28, 2015 , ... • Jeon Jin Bio Corp, a Korean Biotech venture ... , Bird Free, an oil-based, gel formula ... modalities including visual, smell, taste and touch, enabling safe, effective avian control without toxic ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased to announce ... offered in symposia, oral sessions, workshops, awards, and posters. The core of ... applications such as, but not limited to, biotechnology, biomedical, drug discovery, environmental, food ...
(Date:11/26/2015)... November 26, 2015 ... Accutest Research Laboratories, a leading ... Organization (CRO), has formed a strategic ... - Temple Health for joint work ... (Photo: ) , --> ...
Breaking Biology Technology:
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
(Date:10/29/2015)... Connecticut , October 29, 2015 ... a biometric authentication company focused on the growing ... smart wallet announces that StackCommerce, a leading marketplace ... be featuring the Wocket® smart wallet on StackSocial ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
Breaking Biology News(10 mins):